Literature DB >> 18239735

Also the very elderly benefit from warfarin in atrial fibrillation.

F W A Verheugt1.   

Abstract

Entities:  

Year:  2007        PMID： 18239735      PMCID： PMC2213448          DOI： 10.1007/bf03086039

Source DB:  PubMed          Journal:  Neth Heart J        ISSN： 1568-5888            Impact factor:   2.380


× No keyword cloud information.
  9 in total

Review 1.  Antithrombotic therapy for atrial fibrillation.

Authors:  Gregory Y H Lip; Robert G Hart; Dwayne S G Conway
Journal:  BMJ       Date:  2002-11-02

2.  Anticoagulants in heart disease: current status and perspectives.

Authors:  Raffaele De Caterina; Steen Husted; Lars Wallentin; Giancarlo Agnelli; Fedor Bachmann; Colin Baigent; Jørgen Jespersen; Steen Dalby Kristensen; Gilles Montalescot; Agneta Siegbahn; Freek W A Verheugt; Jeffrey Weitz
Journal:  Eur Heart J       Date:  2007-04-10       Impact factor: 29.983

3.  Stroke prevention in elderly patients with atrial fibrillation.

Authors:  David Garcia; Elaine Hylek
Journal:  Lancet       Date:  2007-08-11       Impact factor: 79.321

4.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Authors:  Gregory W Albers; Hans-Christoph Diener; Lars Frison; Margaretha Grind; Mark Nevinson; Stephen Partridge; Jonathan L Halperin; Jay Horrow; S Bertil Olsson; Palle Petersen; Alec Vahanian
Journal:  JAMA       Date:  2005-02-09       Impact factor: 56.272

5.  Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.

Authors:  B S Hellemons; M Langenberg; J Lodder; F Vermeer; H J Schouten; T Lemmens; J W van Ree; J A Knottnerus
Journal:  BMJ       Date:  1999-10-09

6.  Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

Authors:  Giancarlo Agnelli; Alexander Gallus; Samuel Z Goldhaber; Sylvia Haas; Menno V Huisman; Russel D Hull; Ajay K Kakkar; Frank Misselwitz; Sebastian Schellong
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

7.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.

Authors:  Diane K Wysowski; Parivash Nourjah; Lynette Swartz
Journal:  Arch Intern Med       Date:  2007-07-09

8.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321

9.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Authors:  Jonathan Mant; F D Richard Hobbs; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; Ellen Murray
Journal:  Lancet       Date:  2007-08-11       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.